10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
CVS HEALTH CORP | |||
Ticker: CVS Fiscal Year: 2020 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 16, 2021) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Cash flows from operating activities: | |||
| Cash receipts from customers | $ 264,327 | 248,393 | 186,519 |
| Cash paid for inventory and prescriptions dispensed by retail network pharmacies | (158,636) | (149,655) | (148,981) |
| Insurance benefits paid | (55,124) | (52,242) | (6,897) |
| Cash paid to other suppliers and employees | (29,763) | (28,932) | (17,234) |
| Interest and investment income received | 894 | 955 | 644 |
| Interest paid | (2,904) | (2,954) | (2,803) |
| Income taxes paid | (2,929) | (2,717) | (2,383) |
| Net cash provided by operating activities | 15,865 | 12,848 | 8,865 |
| Cash flows from investing activities: | |||
| Proceeds from sales and maturities of investments | 6,467 | 7,049 | 817 |
| Purchases of investments | (9,639) | (7,534) | (692) |
| Purchases of property and equipment | (2,437) | (2,457) | (2,037) |
| Proceeds from sale-leaseback transactions | 101 | 5 | 0 |
| Acquisitions (net of cash acquired) | (866) | (444) | (42,226) |
| Proceeds from sale of subsidiaries and other assets | 840 | 0 | 832 |
| Other | 0 | 42 | 21 |
| Net cash used in investing activities | (5,534) | (3,339) | (43,285) |
| Cash flows from financing activities: | |||
| Net repayments of short-term debt | 0 | (720) | (556) |
| Proceeds from issuance of long-term debt | 9,958 | 3,736 | 44,343 |
| Repayments of long-term debt | (15,631) | (8,336) | (5,522) |
| Derivative settlements | (7) | (25) | 446 |
| Dividends paid | (2,624) | (2,603) | (2,038) |
| Proceeds from exercise of stock options | 264 | 210 | 242 |
| Payments for taxes related to net share settlement of equity awards | (88) | (112) | (97) |
| Other | (27) | 0 | 1 |
| Net cash provided by (used in) financing activities | (8,155) | (7,850) | 36,819 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 0 | 0 | (4) |
| Net increase in cash, cash equivalents and restricted cash | 2,176 | 1,659 | 2,395 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 5,954 | 4,295 | |
| Cash, cash equivalents and restricted cash at the end of the period | 8,130 | 5,954 | 4,295 |
| Reconciliation of net income (loss) to net cash provided by operating activities: | |||
| Net income (loss) | 7,192 | 6,631 | (596) |
| Reconciliation of net income (loss) to net cash provided by operating activities: | |||
| Depreciation and amortization | 4,441 | 4,371 | 2,718 |
| Goodwill impairments | 0 | 0 | 6,149 |
| Stock-based compensation | 400 | 453 | 280 |
| (Gain) loss on sale of subsidiaries | (269) | 205 | 86 |
| Loss on early extinguishment of debt | 1,440 | 79 | 0 |
| Deferred income taxes | (570) | (654) | 87 |
| Other noncash items | 72 | 264 | 253 |
| Change in operating assets and liabilities, net of effects from acquisitions: | |||
| Accounts receivable, net | (1,510) | (2,158) | (1,139) |
| Inventories | (973) | (1,075) | (1,153) |
| Other assets | 364 | (614) | (3) |
| Accounts payable and pharmacy claims and discounts payable | 2,769 | 3,550 | 2,329 |
| Health care costs payable and other insurance liabilities | (231) | 320 | (311) |
| Other liabilities | 2,740 | 1,476 | 165 |
| Net cash provided by operating activities | 15,865 | 12,848 | 8,865 |
| External Links | |
| CVS HEALTH CORP (CVS) Fiscal Year 2020 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |